What happened with INMB today?
No read yet
Uses news and trading volume to explain the day’s move and how it relates to the market.
Stop guessing. Get the call, a three-month target price, the best and worst cases, and a source for every claim.
INmune Bio is a clinical-stage biotechnology company whose business depends heavily on getting CORDStrom approved for recessive dystrophic epidermolysis bullosa, or RDEB. CORDStrom uses cells derived from donated umbilical cords. The company also develops XPro1595, a protein therapy focused on Alzheimer’s disease, and INKmune, which primes natural killer cells and is being studied for metastatic castration-resistant prostate cancer.
The company has not commercialized a drug. It has earned limited revenue from a license agreement and previously sold mesenchymal stromal cells to a single customer in the United Kingdom, but stock sales have supplied most of its operating funding. It needs additional capital to continue development and pursue commercialization.
INmune Bio cannot market its candidates without FDA approval in the United States or comparable authorization elsewhere. If products are approved, its ability to earn meaningful revenue will depend substantially on government programs, private insurers and other payors covering and reimbursing treatment.
The risk section is the longest, dullest part of the filing. This keeps only what can really hurt you: where it hits, how hard, when it plays out.
Every company claims an edge. Each one is checked against hard numbers like margins and returns: which hold, and which line gives way first.
INmune Bio depends on Xencor’s licensed patents and know-how for XPro1595, its protein treatment being developed primarily for Alzheimer’s disease, and owes Xencor royalties and a share of sublicense payments. Watch changes to those license rights: some Xencor patents have joint owners, which can complicate INmune Bio’s rights and patent enforcement.
Mesoblast offers a commercialization benchmark for INmune Bio’s CORDStrom: both develop ready-to-use donor-derived mesenchymal cell medicines that modulate inflammation, but their leading products target different diseases. Watch Mesoblast’s rollout of Ryoncil to U.S. transplant centers—it shows how this type of cell medicine reaches treatment sites, not demand for CORDStrom itself.
Innate Pharma and INmune Bio both seek to harness natural killer cells against cancer, making clinical validation of that approach relevant to both. Innate Pharma develops therapies that engage these cells or act on immune checkpoints, while INmune Bio’s INKmune primes the cells to attack cancer.
ImmunityBio provides a commercial reference for INmune Bio’s effort to harness natural killer cells against cancer: its ANKTIVA activates those cells, while INKmune primes them to attack cancer. Watch ANKTIVA sales for use with BCG in adults with BCG-unresponsive non-muscle-invasive bladder cancer with carcinoma in situ, with or without papillary tumors; they show uptake in that setting, not proof that INKmune works in prostate cancer.
INmune Bio Inc. earningsThis company
Inmune Bio has little product revenue and relies on financing to fund clinical programs, so this report will show whether its cash use is accelerating.
Read operating cash used alongside cash on hand at quarter-end. A smaller outflow with more cash would mean less immediate pressure to raise funds or cut programs; a larger outflow with less cash would mean financing or development cuts are becoming more pressing.
ImmunityBio, Inc. earningsIBRX
ImmunityBio’s report will show whether patients and providers are taking up its bladder-cancer drug ANKTIVA, a commercial reference for Inmune Bio’s still-investigational immune therapy.
Look at changes in ANKTIVA sales for its approved bladder-cancer use. Rising sales would show patients and providers adopting the treatment, a useful sign of commercial acceptance for Inmune Bio’s field; weak sales would point to limited uptake, but would not establish whether INmune Bio’s INKmune works in prostate cancer.
